DPYSL5 and small cell lung carcinoma: The presence of other SCLC-associated autoantibodies (VGCCs, CV2/CRMP5) in patients has been correlated to slower tumor growth, complete response to therapy, and longer survival in some studies [32,41,42,52,88,137-142].